IP Library Patent Application 18435779
Patent Application
App. No. 18/435,779

CLASS II, TYPE II CRISPR SYSTEMS

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
18/435,779
Abstract

The present disclosure provides for endonuclease enzymes as well as methods of using such enzymes or variants thereof.

Claims (30)

1 - 113 . (canceled)

114 . A method of modifying a target nucleic acid locus, said method comprising contacting said target nucleic acid locus with:

a) an endonuclease comprising a RuvC domain and an HNH domain, wherein said endonuclease comprises a sequence having at least 70% sequence identity to SEQ ID NO: 2; and

b) an engineered guide ribonucleic acid structure configured to form a complex with said endonuclease, wherein said engineered guide ribonucleic acid structure comprises:

i) a guide ribonucleic acid sequence configured to hybridize to a portion of said target nucleic acid locus; and

ii) a ribonucleic acid sequence configured to bind to said endonuclease comprising a sequence having at least 80% sequence identity to nonvariable nucleotides of any one of SEQ ID NOs: 203, 202, 613, or 614,

wherein said complex modifies said target nucleic acid locus.

115 . The method of claim 114 , wherein said endonuclease is an archaeal endonuclease.

116 . The method of claim 114 , wherein said endonuclease is a class 2, type II Cas endonuclease.

117 . The method of claim 114 , wherein said endonuclease further comprises one or more of: an arginine-rich region comprising an RRxRR motif, a domain with PF14239 homology, a recognition (REC) domain, a bridge helix (BH) domain, a wedge (WED) domain, or a PAM interacting (PI) domain.

118 . The method of claim 117 , wherein said arginine-rich region, said domain with PF14239 homology, said recognition (REC) domain, said bridge helix (BH) domain, said wedge (WED) domain, or said PAM interacting (PI) domain comprises a sequence having at least 85% sequence identity to an arginine-rich region comprising an RRxRR motif, a domain with PF14239 homology, a recognition (REC) domain, a bridge helix (BH) domain, a wedge (WED) domain, or a PAM interacting (PI) domain, respectively, of any one of SEQ ID NOs: 1-198, 221-459, 463-612, or 617-668.

119 . The method of claim 114 , wherein said endonuclease comprises one or more nuclear localization sequences (NLSs) proximal to an N-terminus or a C-terminus of said endonuclease.

120 . The method of claim 114 , wherein said endonuclease comprises a sequence having at least 90% sequence identity to SEQ ID NO: 2.

121 . The method of claim 120 , wherein said endonuclease comprises a sequence of SEQ ID NO: 2.

122 . The method of claim 114 , wherein said endonuclease comprises a sequence having less than 80% sequence identity to a SpCas9 endonuclease.

123 . The method of claim 114 , wherein said guide ribonucleic acid sequence is complementary to a eukaryotic, a fungal, a plant, a mammalian, or a human genomic sequence.

124 . The method of claim 114 , wherein said guide ribonucleic acid sequence is 15-24 nucleotides in length.

125 . The method of claim 114 , wherein said ribonucleic acid sequence configured to bind to said endonuclease comprises a sequence having at least 90% sequence identity to nonvariable nucleotides of any one of SEQ ID NOs: 203, 202, 613, or 614

126 . The method of claim 125 , wherein said ribonucleic acid sequence configured to bind to said endonuclease comprises a sequence having at least 95% sequence identity to nucleotides 23-157 of SEQ ID NO: 203, nucleotides 23-93 of SEQ ID NO: 202, nucleotides 23-145 of SEQ ID NO: 613, or nucleotides 23-157 of SEQ ID NO: 614.

127 . The method of claim 126 , wherein said ribonucleic acid sequence configured to bind to said endonuclease comprises a sequence having nucleotides 23-157 of SEQ ID NO: 203, nucleotides 23-93 of SEQ ID NO: 202, nucleotides 23-145 of SEQ ID NO: 613, or nucleotides 23-157 of SEQ ID NO: 614.

128 . The method of claim 114 , wherein said endonuclease and said ribonucleic acid sequence configured to bind to said endonuclease are derived from distinct bacterial species within a same phylum.

129 . The method of claim 114 , wherein said engineered guide ribonucleic acid structure comprises any one of SEQ ID NOs: 203, 202, 613, or 614.

130 . The method of claim 121 , wherein said engineered guide ribonucleic acid structure comprises any one of SEQ ID NOs: 203, 202, 613, or 614.

131 . The method of claim 114 , wherein said engineered guide ribonucleic acid structure comprises a single ribonucleic acid polynucleotide comprising said guide ribonucleic acid sequence and said ribonucleic acid sequence configured to bind to said endonuclease.

132 . The method of claim 114 , wherein said sequence identity is determined by said BLASTP homology search algorithm using parameters of a wordlength (W) of 3, an expectation (E) of 10, and a BLOSUM62 scoring matrix setting gap costs at existence of 11, extension of 1, and using a conditional compositional score matrix adjustment.

133 . The method of claim 114 , further comprising contacting said target nucleic acid locus with a single- or double-stranded deoxyribonucleic acid repair template comprising from 5′ to 3′: a first homology arm comprising a sequence 5′ to said target nucleic acid locus, a synthetic deoxyribonucleic acid sequence, and a second homology arm comprising a sequence 3′ to said target nucleic acid locus.

134 . The method of claim 114 , wherein said modifying comprises binding, nicking, cleaving, or marking said target nucleic acid locus.

135 . The method of claim 114 , wherein said target nucleic acid locus comprises deoxyribonucleic acid (DNA) or ribonucleic acid (RNA).

136 . The method of claim 114 , wherein said target nucleic acid locus is within a cell.

137 . The method of claim 136 , wherein said cell is a eukaryotic cell, an animal cell, a mammalian cell, a rodent cell, a primate cell, or a human cell.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 9, 2024
From: THOMAS, BRIAN; BROWN, CHRISTOPHER; DEVOTO, AUDRA; BUTTERFIELD, CRISTINA; ALEXANDER, LISA; GOLTSMAN, DANIELA S.A.
To: METAGENOMI, INC.
Reel/Frame 066428/0085 →